NCT05583266View on ClinicalTrials.gov

Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)

PHASE4UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

March 3, 2023

Study Completion Date

March 31, 2024

Conditions
Cerebral Small Vessel Diseases
Interventions
DRUG

Pentoxifylline sustained-release tablets

a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets

DRUG

Pentoxifylline sustained-release tablets placebo

Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group

Trial Locations (1)

100050

Beijing Tiantan Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

CSPC Ouyi Pharmaceutical Co., Ltd.

INDUSTRY

lead

Beijing Tiantan Hospital

OTHER

NCT05583266 - Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM) | Biotech Hunter | Biotech Hunter